Core Viewpoint - The company, Four Seasons Pharmaceutical, has announced a strategic investment in Swiss aesthetic company Suisselle SA, marking a significant step in its global expansion strategy in the medical aesthetics industry [2] Group 1: Investment Details - Four Seasons Pharmaceutical will complete its investment in Suisselle SA by September 2025, having signed a subscription agreement [2] - The partnership grants Four Seasons exclusive agency rights for the CELLBOOSTER® product line, allowing deep involvement in its operations and development [2] Group 2: Company Background - Suisselle, established in 2010, is a leading manufacturer of water-light needle products, with its CELLBOOSTER® series utilizing patented CHAC technology [2] - The company has expanded its business to 43 countries, showcasing its international reach and market presence [2] Group 3: Strategic Implications - The collaboration will enable Four Seasons to leverage Suisselle's established platform in Europe to accelerate the promotion and sales of its self-developed medical aesthetic products in European and other overseas markets [2] - The partnership aims to continuously introduce innovative products from Suisselle and other European sources, enhancing the domestic medical aesthetic product portfolio [2] - This investment is described as a key step in Four Seasons' global strategy for its medical aesthetics sector [2]

Group 1 - Jiuan Medical plans to repurchase shares worth no less than 300 million yuan and no more than 600 million yuan, with a maximum repurchase price of 53.5 yuan per share, to maintain company value and shareholder rights [1] - The current share price of 38.19 yuan represents a discount of approximately 28% compared to the repurchase cap, signaling potential valuation recovery [1] - The repurchased shares are intended to be sold within 12 months after the announcement, providing short-term price stability and future funding flexibility for business transformation [1] Group 2 - Lingbei's drug Bexicaserin has been recognized as a breakthrough therapy by the National Medical Products Administration (NMPA) in China for treating developmental epileptic encephalopathy (DEE) [2] - Bexicaserin is a novel oral 5-HT2C receptor agonist designed to reduce cardiovascular risks, marking a significant milestone in Lingbei's development in China [2] Group 3 - Four Rings Pharmaceutical has announced an investment in Swiss medical aesthetics company Suisselle SA, strengthening their long-term partnership [3] - This investment allows Four Rings to maintain exclusive rights to the CELLBOOSTER® product in China and participate deeply in its operations and development [3] - The collaboration aims to accelerate the promotion and sales of Four Rings' self-developed aesthetic products in Europe and other overseas markets [3] Group 4 - Fudan Zhangjiang's application for the drug Obechol acid tablets for treating primary biliary cholangitis was not approved by the NMPA due to non-compliance with registration requirements [4] - The project has incurred approximately 125 million yuan in R&D investment, which will not significantly impact the company's current financial status [4] - The company needs to review the reasons for the rejection and optimize its pipeline to enhance future R&D efficiency [4] Group 5 - Sunshine Nuohuo's BTP4507 has received approval for clinical trials from the NMPA, targeting primary hypertension patients with inadequate response to monotherapy [5] - BTP4507 is a compound formulation designed to address multiple hypertension targets, catering to the needs of over 300 million hypertensive patients in China [5] - If successful in clinical trials, this drug could open new growth avenues for the company, although it will face competition from similar combination therapies [5]

Major Events - Four Seasons Pharmaceutical (00460) invests in Swiss Suisselle to accelerate global medical aesthetics business expansion [1] - Basilea Pharmaceutica-B (02616) to announce Phase I dose-escalation clinical data for PD-1/VEGF/CTLA-4 triple antibody and latest research design for ROR1 ADC [1] - Hengrui Medicine (01276) subsidiary receives drug clinical trial approval notice [1] - Huajian Medical (01931) acquires U.S. property and establishes U.S. subsidiary ETHK BANK to promote stablecoins and intellectual property securitization in the U.S. [1] - China National Pharmaceutical Group (01177): TQB2102 "HER2 dual antibody ADC" included in breakthrough therapy designation program [1] Operating Performance - 361 Degrees (01361): Retail sales of 361° main brand products in Q3 increased by approximately 10% year-on-year [1] - Xinhua Insurance (01336) expects net profit attributable to shareholders for the first three quarters to increase by 45% to 65% year-on-year [1] - Country Garden (02007) achieved contract sales amounting to approximately 2.58 billion yuan in September [1] - Dekang Agriculture and Animal Husbandry (02419) sold approximately 7.55 million pigs and generated sales revenue of approximately 14.28 billion yuan in the first nine months [1] - Longfor Group (00960) achieved total contract sales amount of 50.75 billion yuan in the first nine months [1]

四环医药(00460)发布公告，于2025年10月13日，受托人已就股份奖励计划于市场上购买合共1000万股 本公司股份(股份)。 ...

智通财经APP讯，四环医药(00460)发布公告，于2025年10月13日，受托人已就股份奖励计划于市场上购 买合共1000万股本公司股份(股份)。 ...

格隆汇10月13日丨四环医药(00460.HK)公布，于2025年10月13日，受托人已就股份奖励计划于市场上购 买合共1000万股公司股份，每股平均代价约1.619港元。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 Sihuan Pharmaceutical Holdings Group Ltd. 四環醫藥控股集團有限公司 （於百慕達註冊成立的有限公司） （股份代號：0460） 自願公告 根據股份獎勵計劃購買股份 此 乃 四 環 醫 藥 控 股 集 團 有 限 公 司（「本公司」或「四環醫藥」，連 同 其 附 屬 公 司， 統 稱 為「本集團」）作 出 的 自 願 公 告。 兹 提 述 本 公 司 日 期 為 二 零 二 二 年 十 月 二 十 六 日 的 公 告（「該公告」），內 容 有 關（其 中 包 括）本 公 司 採 納 二 零 二 二 年 股 份 獎 勵 計 劃（「股份獎勵計劃」）。除 文 義 另 有 所 指 外，本 公 告 所 用 詞 彙 與 該 公 告 所 界 定 者 具 有 相 同 涵 義。於 二 零 二 五 年 十 月 十 三 日，受 託 人 ...

Core Viewpoint - The company has signed an investment agreement to acquire a stake in Swiss aesthetic company Suisselle SA, enhancing its strategic relationship and expanding its presence in the global aesthetic market [1][2] Group 1: Investment Details - The investment in Suisselle will allow the company to permanently hold exclusive agency rights for the CELLBOOSTER product in China, strengthening long-term collaboration [1] - The partnership will leverage Suisselle's established platform in Europe to accelerate the promotion and sales of the company's self-developed aesthetic products in European and other overseas markets [1] Group 2: Strategic Expansion - The investment marks a significant step in the company's global strategy for the aesthetic business, completing its strategic layout in the core aesthetic markets of Europe and North America [2] - The company aims to continue driving high-quality aesthetic solutions through a combination of independent research and international collaboration, creating long-term sustainable value for shareholders and investors [2]

Core Insights - Four Seasons Pharmaceutical (00460) has signed an investment subscription agreement to acquire a stake in Swiss medical aesthetics company Suisselle SA, aiming to enhance their strategic relationship and expand in the global medical aesthetics market [1][2] - The company previously secured exclusive agency rights for the CELLBOOSTER water needle in China in 2022, and this investment will solidify their long-term partnership, granting permanent exclusive agency rights for the product [1] - The collaboration will leverage Suisselle's established platform in Europe to accelerate the promotion and sales of the company's self-developed medical aesthetic products in Europe and other overseas markets [1] - The investment aligns with the company's globalization strategy, aiming to build an international medical aesthetics ecosystem covering research, production, and sales [1] Strategic Developments - The company has been actively pursuing a global strategy in the medical aesthetics sector, having fully acquired American medical aesthetics equipment company Genesis Biosystems in 2021, marking its entry into the North American market [2] - The investment in Suisselle represents a critical step in the company's global strategy, completing its strategic layout in the core medical aesthetics markets of Europe and North America [2] - The company plans to continue driving high-quality medical aesthetic solutions through a dual approach of independent research and international collaboration, aiming to create long-term sustainable value for shareholders and investors [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 Sihuan Pharmaceutical Holdings Group Ltd. 四環醫藥控股集團有限公司 （於百慕達註冊成立的有限公司） （股份代號：0460） 自願公告 四環醫藥投資入股瑞士Suisselle公 司 加速全球化醫美業務布局 CELLBOOSTER®為瑞士制造的創新水光針（歐洲III類醫療器械），憑借其專利CHAC 技 術 實 現 成 分 穩 定 與 高 效 遞 送，涵 蓋 多 維 度 皮 膚 問 題 解 決 方 案： 四 環 醫 藥 控 股 集 團 有 限 公 司（「本公司」或「四環醫藥」，連 同 其 附 屬 公 司，統 稱 為 「本集團」）董 事 會（「董事會」）欣 然 宣 佈，本 集 團 於 二 零 二 五 年 九 月 對 瑞 士 醫 美 公 司Suisselle SA（「Suisselle」）進 行 投 資 入 股，雙 ...